Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 3
1948 4
1965 1
1966 1
1967 1
1969 2
1971 1
1973 1
1981 1
1982 2
1983 3
1984 2
1985 4
1986 5
1987 6
1988 10
1989 13
1990 11
1991 6
1992 7
1993 21
1994 16
1995 12
1996 19
1997 21
1998 20
1999 13
2000 25
2001 19
2002 23
2003 16
2004 20
2005 24
2006 33
2007 22
2008 19
2009 17
2010 18
2011 28
2012 26
2013 36
2014 44
2015 49
2016 42
2017 59
2018 58
2019 50
2020 13
Text availability
Article attribute
Article type
Publication date

Search Results

766 results
Results by year
Filters applied: . Clear all
Page 1
Systemic amyloidosis
Wechalekar AD, et al. Lancet 2016 - Review. Among authors: Hawkins PN. PMID 26719234
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams D, et al. N Engl J Med 2018 - Clinical Trial. Among authors: Hawkins PN. PMID 29972753 Free article.
The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) change from baseline was -6.0±1.7 versus 28.0±2.6 (difference, -34.0 points; P<0.001) at 18 months. ...At 18 months, the least-squares mean change from baseline in gait speed was 0.08±0.02 m per second with patisiran versus -0.24±0.04 m per second with placebo (difference, 0.31 m per second; P<0.001), and the least-squares mean change from baseline in the modified BMI was -3.7±9.6 versus -119.4±14.5 (difference, 115.7; P<0.001). ...
The mean (±SD) mNIS+7 at baseline was 80.9±41.5 in the patisiran group and 74.6±37.0 in the placebo group; the least-squares mean (±SE) chan …
Cardiac amyloidosis
Martinez-Naharro A, et al. Clin Med (Lond) 2018 - Review. Among authors: Hawkins PN. PMID 29700090 Free PMC article.
PTEN Regulates PI(3,4)P(2) Signaling Downstream of Class I PI3K.
Malek M, et al. Mol Cell 2017. Among authors: Hawkins PT. PMID 29056325 Free PMC article.
Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P(3). PI(3,4,5)P(3) can be dephosphorylated by 3- or 5-phosphatases, the latter producing PI(3,4)P(2). ...Here we show that PTEN also functions as a PI(3,4)P(2) 3-phosphatase, both in vitro and in vivo. PTEN is a major PI(3,4)P(2) phosphatase in Mcf10a cytosol, and loss of PTEN and INPP4B, a known PI(3,4)P(2) 4-phosphatase, leads to synergistic accumulation of PI(3,4)P(2), which correlated with increased invadopodia in epidermal growth factor (EGF)-stimulated cells. ...
Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P(3). PI(3,4,5)P(3) can be dephosphorylated by 3- or 5-phosphatases, the …
A new staging system for cardiac transthyretin amyloidosis
Gillmore JD, et al. Eur Heart J 2018. Among authors: Hawkins PN. PMID 29048471
Median survival among 393 (45%) Stage I patients was 69.2 months, 334 (38%) Stage II patients was 46.7 months, and 142 (16%) Stage III patients was 24.1 months (P < 0.0001). After adjusting for age, compared with Stage I, the hazard ratio (HR) for death for Stage II was 2.05 [confidence interval (CI) 1.54-2.72, P < 0.001] and for Stage III was 3.80 (CI 2.73-5.28, P < 0.001). ...
Median survival among 393 (45%) Stage I patients was 69.2 months, 334 (38%) Stage II patients was 46.7 months, and 142 (16%) Stage III patie …
PI3K signalling in inflammation
Hawkins PT and Stephens LR. Biochim Biophys Acta 2015 - Review. PMID 25514767 Free article.
Magnetic Resonance in Transthyretin Cardiac Amyloidosis
Martinez-Naharro A, et al. J Am Coll Cardiol 2017. Among authors: Hawkins PN. PMID 28728692 Free article.
ECV independently correlated with mortality and remained independent after adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E', and left ventricular mass (hazard ratio: 1.164; 95% confidence interval: 1.066 to 1.271; p < 0.01). ...
ECV independently correlated with mortality and remained independent after adjustment for age, N-terminal pro-B-type natriuretic peptide, ej …
766 results
Jump to page
Feedback